AbbVie, a global biopharmaceutical company, today announced that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for Humira (adalimumab) for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adult patients with an inadequate response to conventional systemic hidradenitis suppurativa (HS) therapy. 

HS is a painful, chronic inflammatory skin disease estimated to impact approximately 1 percent of the adult population worldwide. If granted marketing authorization by the European Commission, Humira will become the first and only medication approved for HS.

"The positive opinion from the CHMP is a significant milestone for people with HS in Europe because it represents progress toward the first and only approved medicine for this devastating disease," said Michael Severino, M.D., executive vice president, research and development and chief scientific officer, AbbVie. "If approved, Humira could offer new hope to people impacted by moderate to severe HS, and this demonstrates AbbVie's ongoing commitment to innovation with Humira to provide new solutions for difficult-to-treat diseases."

For more details, go to: http://abbvie.mediaroom.com/2015-06-26-AbbVies-HUMIRA-Adalimumab-Receives-Positive-CHMP-Opinion-to-Treat-Adult-Patients-with-Active-Moderate-to-Severe-Hidradenitis-Suppurativa-a-Chronic-Inflammatory-Skin-Disease